chrisvoncsefalvay/vaers-outcomes huggingface dataset:
I experienced pain in my whole body and a great deal of fatigue. This lasted about 3 days. I took Advil for the pain.
The pt experienced a few papules on trunk and hand, no vesicles, some are crusted.
Itchyness, first evening in hands, next afternoon  severe over both legs  for a couple of hours
Pt describes at time of vaccine feeling an"electric shock like pain as if it hit the nerve. C/O constant throbbing in Left arm. Stated it hurts more when lifting her arm radiating pain from Left arm to her elbow. Flu like symptoms for several days. No other symptoms.
innoculation given 18MAR93 & rash w/fever occurred 1 wk p/-lasted 2 days;
Patient mistakenly received a second dose of the bivalent booster only 2 weeks after receiving her first dose of the bivalent booster. No adverse events occurred.
Dr. prescribed a 3rd dose; 1st dose 26Sep2019, 2nd 07Feb2023; This non-serious case was reported by a nurse via call center representative and described the occurrence of drug dose administration interval too long in a 56-year-old female patient who received Herpes zoster (Shingrix) (batch number 2722H, expiry date 08-FEB-2024) for prophylaxis.   Co-suspect products included Herpes zoster (Shingrix) for prophylaxis.   Previously administered products included Shingrix (received first dose on 26th September 2019).   On 07-FEB-2023, the patient received the 2nd dose of Shingrix. On an unknown date, the patient received the 3rd dose of Shingrix. On 07-FEB-2023, an unknown time after receiving Shingrix and not applicable after receiving Shingrix, the patient experienced drug dose administration interval too long (Verbatim: 1st dose 26Sep2019, 2nd 07Feb2023). On an unknown date, the patient experienced drug prescribing error (Verbatim: Dr. prescribed a 3rd dose). The outcome of the drug dose administration interval too long and drug prescribing error were unknown.   Additional Information: GSK receipt date: 7-Apr-2023 The reporter asked that was that correct. The vaccine administration facility was the same as primary reporter. The reporter did not consent to follow-up. The patient received second dose of Shingrix later than the recommended interval, which led to lengthening of vaccine schedule. A physician prescribed third dose to the patient, which led to drug prescribing error.
RIGHT AFTER THE VACCINE SHE WAS PALE AND FAINTED, SHE BECAME VERY TIRED AND SLEPT FOR THE REST OF THE DAY.
The injection of the vaccine in my right deltoid muscle was much more painful than any other that I'd gotten previously (many).It continued to hurt for months, causing loss of range of motion, and also pain in shoulder neck and back. I took muscle relaxants, anti-inflammatories, physical therapy, moist heat, with little relief. The deltoid muscle has atrophied and I am going to another physical therapist currently.
Systemic: Hypotension-Mild, Systemic: Seizure-Mild, Additional Details: after a few minutes of monitoring patient started convulsing it appears like. she was sitting in a chair and started shaking with her head back for about 10 seconds. she does not remember this happening and reported she bit her mouth or tongue in the process. she slightly felt dizzy but that resolved in a few seconds. she reported felt some hotness and tingling at injection site, gave her water monitored more and she felt normal again, no history of seizures she reports. not sick either
Hot and cold; Swelling in abdomen; Swelling in her abdomen, ankles, and feet; Swelling in her abdomen, ankles, and feet; Exhaustion; Chills; This spontaneous case was reported by a consumer (subsequently medically confirmed) and describes the occurrence of FEELING OF BODY TEMPERATURE CHANGE (Hot and cold), ABDOMINAL DISTENSION (Swelling in abdomen), JOINT SWELLING (Swelling in her abdomen, ankles, and feet), PERIPHERAL SWELLING (Swelling in her abdomen, ankles, and feet) and FATIGUE (Exhaustion) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     Concurrent medical conditions included Diabetes, Hypertension and Thyroid disorder NOS.    On 11-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 11-Mar-2021, the patient experienced FEELING OF BODY TEMPERATURE CHANGE (Hot and cold), ABDOMINAL DISTENSION (Swelling in abdomen), JOINT SWELLING (Swelling in her abdomen, ankles, and feet), PERIPHERAL SWELLING (Swelling in her abdomen, ankles, and feet), FATIGUE (Exhaustion) and CHILLS (Chills). At the time of the report, FEELING OF BODY TEMPERATURE CHANGE (Hot and cold), ABDOMINAL DISTENSION (Swelling in abdomen), JOINT SWELLING (Swelling in her abdomen, ankles, and feet), PERIPHERAL SWELLING (Swelling in her abdomen, ankles, and feet), FATIGUE (Exhaustion) and CHILLS (Chills) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Relevant concomitant medications included diabetes medication,blood pressure medication and thyroid medication (dose recently increased). No treatment information was provided.
Pt was 18 weeks pregnant, no fetal heartbeats detected at OB/Gyn visit on Dec 2 09. IUFD, D&C done Dec 3 09
Patient received her second Pfizer vaccine and approximately 15 minutes after noted that her arm that the vaccine was given in was numb. Upon assessment she was unable to lift her arm, she could not "feel" her arm and had decreased grip strength in the arm the vaccine was given. Ice applied, no change after being observed. Patient was sent to Urgent Care downstairs for further observation.
4:00 PM 06/19/07 HA, dizzy, nauseous, "breathing hard". 5:15 PM 06/19/07 Dizzy, nauseous, "hard to take a breath" 5:30 PM 06/19/07 Dizzy, nauseous, chest tight "hard to take a breath". No treatment at this time other than an Advil for HA. Recommend to see doctor if S/S get worse.
Patient has not experienced an adverse event. Patient got the Pfizer COVID vaccine after intentionally witholding information of a previous COVID vaccine. Information of previous COVID administration was obtained while billing the Pfizer vaccine administration through his insurance. He said he decided to get it because he heard Dr. TV saying a booster vaccination may be required after getting the vaccine.
PATIENT RECEIVED VACCINE FROM OUTSIDE SOURCE ACUTE NON ST ELEVATION MI 10/29/2022 -- RECURRENCE OF SAME SYMPTOMS
I had the flu shot on the same day in the same arm. The day after I was fine. On the second day I could not get out of bed.  I had a very high fever (enough to not make sense when talking; highest recorded was 102.6), abdominal swelling, other generalized swelling, joint pain, muscle pain, couldn't breathe well (I think from the abdominal swelling), severe chills, pain under my left rib which seemed to be at my spleen (perhaps enlarged), complete exhaustion, back pain, found it difficult to turn over in bed, could hardly get out of bed. This lasted for eight full days.  Only today, day nine, am I starting to feel better.
Right side of my face  blew up , my neck had a lump the size of orange and was extremely sore. When I swallowed it hurt like the mumps. My neck is still has a lump the size of an walnut.
a 62 y.o. female with a history of shortness of breath and cough has been present for about the last week. Patient states she's felt that for approximately 2 years atrophy diagnosis stage IV lung cancer she states over last week she's had an increased amount of cough congestion short of breath normally wears 2 L at home but has had to turn it up due to shortness of breath has had a lot of wheezing using breathing treatments at home without success cough will not clear she's had no nausea no vomiting but appetite and decreased she has had about a 60 pound weight loss over last 6 months. Denies chest pain bowels have moved without diarrhea patient seen in emergency room noted have bacterial pneumonia as well as Covid pneumonia. Patient follows with oncology for stage IV lung cancer on immunotherapy.  Patient requests dnr code status".   Hospital Course:  The patient was admitted to the hospital and was evaluated and treated per below.      * Acute on chronic respiratory failure with hypoxia Description of the Problem/Progression:  Plan:  o Pneumonia due to Covid 19 virus with acute respiratory failure with hypoxia. Improving on current treatment. Completed Remdesivir course D5/5.  Continues on IV Solu-Medrol, transitioned to PO tapering course of Prednisone. Weaned oxygen back to oxygen baseline at 2 L. Will taper Decadron to ONCE DAILY. Nebs and inhalers as ordered. Continue to follow up daily inflammatory markers and d-dimer. Continue nebs and inhalers. Encourage incentive spirometry use and pronating. Continue supportive/symptomatic treatment and supplements as ordered per COVID protocol. Follow up daily lab.  o Strep pneumonia bacteremia. Followed by infectious diseases, consult appreciated. Remains on Rocephin. Repeat blood cultures remained no growth at 96 hours. Sputum culture is pending, patient is unable to produce. Status post pleural tap with only 4 cc retrieved. o COPD with acute exacerbation. Improved. Continue nebs, and inhalers, and weaned off IV Solu-Medrol per above. o Pleural effusion. Interventional radiology consulted for possible pleural tap. o Elevated d-dimer. Repeat CTA of the chest shows no pulmonary embolus. However there is evidence of possible spleen hematoma versus other etiologies. Patient is also anemic. Concern about possible splenic hemorrhage versus infarct. Holding anticoagulation. Switched to SCDs for DVT prophylaxis. General surgery consulted. CT of the abdomen and pelvis ordered with IV contrast showing splenic infarct in addition to worsening omental metastasis. Pulmonary consulted palliative care. Patient requested hospice evaluation. She requested discharge home with hospice.   o Anemia with positive occult blood. Workup otherwise is unremarkable for any B12, iron or folate deficiencies. GI consulted. Endoscopy only with overt bleeding. Continue to monitor H&H which remain stable.  o Stage IV lung CVA. On immunotherapy outpatient. Per above.
.5 mL was given intradermally instead of subcutaneously. PT did not reply to multiple attempts of contact. Results unknown. No adverse events known.
injection site pain; fatigue; headache; fuzzy headedness; muscle pain; joint pain generally with focus on left knee; This is a spontaneous report from a contactable consumer, the patient. A 70-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6201) via an unspecified route of administration in the arm left on 12Feb2021 at 01:00 (at the age of 70-years-old) and second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6198) via an unspecified route of administration in the arm left on 05Mar2021 (at the age of 70-years-old) as a single dose for COVID-19 immunisation. The patient medical history included seasonal allergies. The patient did not receive any concomitant medications. The patient did not receive any other vaccines within 4 weeks prior to the COVID-19 vaccine. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient was not tested for COVID-19. On 12Feb2021, the patient experienced injection site pain (vaccination site pain), fatigue, headache, fuzzy headedness, muscle pain and joint pain generally with focus on left knee. The reported adverse events did not result in a visit to the doctors or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The patient received chiropractic treatment at 6 weeks from the first dose. The clinical outcomes of the events injection site pain, fatigue, headache, fuzzy headedness, muscle pain, joint pain generally with focus on left knee were resolving at the time of report.   No follow-up attempts are needed. No further information is expected.
Classic post MMR rash -  maculopapular rash on trunk and head  that started 8 days after MMR vaccine.  It started first around umbilicus and then spread to rest of trunk. Cheeks also became red. Bumpy red spots also spread to head.  Temp max 99.8 at home.  Full recovery is anticipated.
pt recv vax & shortly afterward pt exp a rapidly deteriorating condition & was hosp;pt died;COD was not reported;
I woke up with a dry heave but I was unable to throw anything up. It then switched over to diarrhea. After being in the bathroom for a while, I laid back down and went back to sleep. For the remainder of the day I felt like I was coming down with the flu. I experienced body aches and lethargy. I took Aleve D to to treat the symptoms. I did experience a loss of appetite. When I woke up the next morning I felt 100% better.
This spontaneous report as received from a physician refers to a male patient of unknown age. The patient's pertinent medical history, drug reactions/allergies were not provided. On 05-AUG-2012, the patient was vaccinated with a first dose of GARDASIL, (route, lot number and expiration date were not provided). It was reported that in August 2013, the patient received a second dose of GARDSAIL, (route, lot number and expiration date were not provided. Additional information is not expected since physician would not like to be contacted.
Information has been received from a physician concerning a female who was vaccinated with GARDASIL. Subsequently the patient experienced syncope. Unspecified medical attention was sought. At the time of the report the patient recovered. Additional information has been requested.
Almost 2 weeks after vaccination, client reported that she had itching, nausea and broke out in <50 small, red blisters. The itching started 4/20/06 and one broke out 4/21/06. The rash lasted about 3 days. Client denies any fever. No treatment was needed.
Migraine with aura 4/4/21 and 4/10/21. I also had a temperature of 100.4 after the first shot. My normal temperature prior to that was usually around 96.2-97.6.
Fainted - Vagal Reaction blood pressure when I came to ED was 83/53
Paramedic on location reported that patient received her first shot of Pfizer vaccine and patient had a syncopal episode. Paramedics reported that the patient was unresponsive with snoring respirations.  IV normal saline started and patient transported to ED.  On arrival patient stated she has had syncopal episodes with needle sticks in the past.  EKG and lab work normal Patient discharged in stable condition.
18 days post vax the pt developed a varicella like rash from head to toe that consisted of greater than 50 lesions and a fever. The reporting physician felt that the varicella like rash was not related to varicella virus vaccine live. Two additional pts had similar experienced following exposure to varicella virus vaccine live. Additional information has been requested.
patients have been administered doses while the temperature excursion assessment was ongoing (possible temperature excursion); patients have been administered doses while the temperature excursion assessment was ongoing (possible temperature excursion); This spontaneous case was reported by an other health care professional and describes the occurrence of PRODUCT TEMPERATURE EXCURSION ISSUE (patients have been administered doses while the temperature excursion assessment was ongoing (possible temperature excursion)) and POOR QUALITY PRODUCT ADMINISTERED (patients have been administered doses while the temperature excursion assessment was ongoing (possible temperature excursion)) in a 57-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) .25 milliliter. On an unknown date, the patient experienced PRODUCT TEMPERATURE EXCURSION ISSUE (patients have been administered doses while the temperature excursion assessment was ongoing (possible temperature excursion)) and POOR QUALITY PRODUCT ADMINISTERED (patients have been administered doses while the temperature excursion assessment was ongoing (possible temperature excursion)). At the time of the report, PRODUCT TEMPERATURE EXCURSION ISSUE (patients have been administered doses while the temperature excursion assessment was ongoing (possible temperature excursion)) and POOR QUALITY PRODUCT ADMINISTERED (patients have been administered doses while the temperature excursion assessment was ongoing (possible temperature excursion)) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No concomitant medication was provided.  It was reported that, there was no power outages that would have impacted the Moderna vaccine. However, the healthcare professional reiterates that because her facility was unable to download the digital data logger, they needed to treat this issue as a temperature excursion. The data logger was unable to download for the months of Dec-2021, Jan-2022, and Feb-2022. They were filling out a temperature excursion assessment with the state at this time. It was also reported that, no adverse reactions were reported by the patient.  No treatment medication was provided.
Knot started forming within first 24hrs.  Continued to swell and discolor.  Day 6 sought medical attention large egg shap and dark discoloration at vaccination site. Day 7 mutliple pustules started forming.  Day 8 pustules started to burst.
Pt recvd vax approx 1130AM & by 1230PM pt began screaming & crying w/ a high pitched cry; pt had high pitched crying was reported to have lasted approx 3 hrs;
I was on vacation  and on our way home from vacation, on 5/26/22, I noticed that I had a runny nose, congestion, sneezing, and itchy throat. I tested positive for COVID-19 on 5/27/2022. I am still dealing with my symptoms at this time. I can feel phlegm in my throat, but nothing ever comes out.
This case was reported by a pharmacist via call center representative and described the occurrence of injection site pain in a 41-year-old male patient who received HAVRIX 1440 (batch number PZ353, expiry date 21st November 2020). On 2nd May 2018, the patient received the 1st dose of HAVRIX 1440. On 2nd May 2018, less than a day after receiving HAVRIX 1440, the patient experienced injection site pain, injected limb mobility decreased and numbness in fingers. On an unknown date, the outcome of the injection site pain, injected limb mobility decreased and numbness in fingers were unchanged. The reporter considered the injection site pain, injected site limb mobility decreased and numbness in fingers to be almost certainly related to HAVRIX 1440. Additional information was received as follows: The patient received HAVRIX 1440 on the left arm. The patient experienced arm pain and difficulty in raising the arm.
Local edema, erythema and erythema marginatum. (Given Benadryl and Orapned). Pt seen at emergency room 4 days prior.
28APR92 pt recvd Engerix-B & same day exp rash on rt arm; small amount of swelling on rt arm; felt like no circulation in rt arm; 29APR92 pt's face felt like a rash; 30ARP92 pt given DPH;
No adverse event; Administered a booster instead of a second dose; This spontaneous case was reported by a pharmacist and describes the occurrence of WRONG PRODUCT ADMINISTERED (Administered a booster instead of a second dose) and NO ADVERSE EVENT (No adverse event) in a 27-year-old female patient who received mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (batch no. 062S22A) for COVID-19 prophylaxis.     Question:Describe relevant medical history/conditions, allergy, concomitant diseases and risk factor.Answer:No Allergy No Diseases.  Concomitant products included ELASOMERAN (SPIKEVAX) for COVID-19 prophylaxis.    On 27-Dec-2022, the patient received second dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (unknown route) .5 milliliter. On 27-Dec-2022,  after starting mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)), the patient experienced WRONG PRODUCT ADMINISTERED (Administered a booster instead of a second dose). On an unknown date, the patient experienced NO ADVERSE EVENT (No adverse event). At the time of the report, WRONG PRODUCT ADMINISTERED (Administered a booster instead of a second dose) and NO ADVERSE EVENT (No adverse event) outcome was unknown.        For mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (Unknown), the reporter considered NO ADVERSE EVENT (No adverse event) to be not related. No further causality assessment was provided for WRONG PRODUCT ADMINISTERED (Administered a booster instead of a second dose).    Concomitant medication was not reported. Patient had no allergy.  Patient does not receive any other vaccines in the 4 weeks prior to COVID-19 vaccine. Treatment drug was not reported.
Redness around injection site, raised bump that is warm to touch and tender, shoulder pain down to elbow. Reported to Employer at 4:30pm 1/20/21. Employee health recommended an ice pack and ibuprofen for discomfort. Instruction to present to Urgent Care should symptoms worsen.
Vaccine administration error.  The patient is 17.  It is not FDA approved for anyone under the age of 18 to get a Pfizer COVID 19 booster or 3rd dose.   The patient reported no adverse effects.
Started today around 9:00 am. Site on right arm is swollen, red and hot to the touch. Around noon today started extreme bodyaches, and as time increased got a terrible headache, low-grade fever, and exhaustion.
Fever up to 99.7, chills, bodyache, muscle spasms or twitching in legs, weakness, head pain
Initial misuse report received from health care professional on 29 Oct 2013 and on 21 March 2013. It was reported that female patient (age not reported) had received a dose of FLUZONE on 15 October 2013 and stated that large amounts of fluid flowed down her arm. No adverse event was reported. List of documents held by sender: none.
fever of 103.5, severe vomiting, uncontrollable chills, lower back pain.
Initial unsolicited report received from a nurse on 13 October 2016. This case involves a patient (age and gender were not reported) who was vaccinated with FLUZONE INTRADERMAL (batch number, expiry date, dose, dose in series, route and site of administration) on an unspecified date. The patient's medical history and concomitant medications were not reported. On an unspecified date, following the vaccination, patient complained of extreme nausea. Laboratory data and corrective treatment were not reported. The outcome of the event was not reported. List of documents held by sender: none.
My son had a generalized tonic clonic seizure that lasted 16 minutes and required 2 doses of Valium from the paramedics to stop it.  He was admitted to the hospital overnight for observation.
DEVELOPED CHILLS AND LIGHTHEADEDNESS AFTER VACCINATION (AROUND 11:30 AM); WAS GIVEN BENADRYL TO TAKE HOME SINCE SHE IS DRIVING HOME ( 11:50 AM)
Within minutes developed erythema and swelling which increased as time passed. Some shortness of breath history of asthma.